Considerations in Management for Trans and Gender Diverse Patients with Inherited Cancer Risk

被引：7

作者：

Coad, Beth ^{[1
,2
]}

Giblin, Josephine ^{[3
,4
]}

Walsh, Reubs J. ^{[5
,6
,7
]}

Kuczkowska, Oliwia ^{[1
]}

von Vaupel-Klein, Alexander M. ^{[8
]}

Berner, Alison ^{[9
,10
]}

机构：

[1] St Georges Hosp NHS Fdn Trust, South West Thames Reg Genom Serv, London, England

[2] St Georges Univ London, London, England

[3] Univ Hosp Southampton Fdn Trust, Wessex Clin Genet Serv, Southampton, Hants, England

[4] NHS Cent & South Genom Med Serv Alliance, London, England

[5] Vrije Univ Amsterdam, Fac Behav & Movement Sci Neuro & Dev Psychol, Dept Clin, Amsterdam, Netherlands

[6] Gender Ident Res & Educ Soc GIRES, Ashtead, England

[7] Ctr Appl Transgender Studies CATS, Chicago, IL USA

[8] Univ Utrecht, Med Ctr, Fac Med, Utrecht, Netherlands

[9] Barts Canc Inst, Genom & Computat Biol, London, England

[10] Tavistock & Portman NHS Fdn Trust, Gender Ident Clin, London, England

来源：

CURRENT GENETIC MEDICINE REPORTS | 2021年 / 9卷 / 04期

关键词：

Cancer risk; Transgender; Genetics; Personalised care; TRANSGENDER;

D O I：

10.1007/s40142-021-00201-6

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Purpose of Review To best support all patients with inherited cancer risk, we must broaden our scope of practice to consider the needs of the transgender and gender diverse (trans) community. We considered best practice for supporting trans patients including tailored risk assessments and management recommendations. Recent Findings There is limited literature considering trans patient care in cancer genetics. Small case studies have highlighted how medical transition and cancer risk-reducing options intersect with the need for individualised care. Studies have also shown that cancer genetics professionals do not feel prepared to support trans patients. Patient-centred care for trans patients relies on a multidisciplinary team (MDT) engaged in shared decision-making. National guidelines are needed to standardise access to appropriate discussions around risk-reducing options and screening. International collaborative research is required to provide empiric data on the impact of gender-affirming treatments on cancer risk, and more experiential data is needed from trans patients accessing cancer genetics services. Finally, education and training in this area should be formally embedded for all cancer genetics professionals.

引用

页码：59 / 69

页数：11

共 43 条

[1] Female-to-Male Gender-Affirming Chest Reconstruction Surgery [J].